Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02206607 · ClinicalTrials.gov registry record · Phase 1
Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02206607 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 39 participants.
The verdict
NCT02206607, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of PF-04937319 compared with the immediate release material-sparing-tablet (IR MST) formulation in adults with type 2 diabetes.
Interventions
- DRUG PF-04937319 IR MST
- DRUG PF-04937319 MR 1
- DRUG PF-04937319 MR 2
- DRUG PF-04937319 MR 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02206607
The ClinicalTrials.gov registry entry for NCT02206607 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PF-04937319 IR MST is the first listed.
NCT02206607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02206607 about?
NCT02206607 is a clinical study titled "Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.". Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of PF-04937319 compared with the immediate release material-sparing-tablet (IR MST) formulation in adults with type 2 diabetes.
What is the current status of trial NCT02206607?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2014-09. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02206607?
The interventions under investigation include: PF-04937319 IR MST (DRUG), PF-04937319 MR 1 (DRUG), PF-04937319 MR 2 (DRUG), PF-04937319 MR 3 (DRUG).
Who is sponsoring clinical trial NCT02206607?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.